🟢 Outlook Therapeutics is trading 6.2% up today on FDA acceptance of BLA for ONS-5010

Outlook Therapeutics is trading 6.2% up at $1.81 as investors position ahead of a key regulatory milestone for its lead retinal therapy.

• The FDA has accepted the resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA, an investigational treatment for wet age-related macular degeneration (wet AMD).
• A PDUFA action date has reportedly been set for late July 2026, maintaining regulatory momentum and providing a clear timeline for the company's primary clinical asset.
• The positive price action reflects growing investor confidence following the formal acceptance of the filing after previous regulatory delays.